Uncategorized

BMS’ ‘big beat’ clouded by Cobenfy, heart disease data delays

Published

on

Strong quarterly results are prompting Bristol Myers Squibb to lift its 2026 outlook, though the company is facing another delay for key Cobenfy Alzheimer’s data and a pushed-back readout for milvexian.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version